Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 152

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 152
---
 at 36%, 21% and 19%. At December 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 18% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2025 and December 31, 2024, there were $0.4 million of allowances for credit losses on the Company’s accounts receivable.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 24

NOTE 11—STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive IncomeThe following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income for the periods presented (in thousands):Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2024$190 $153 $343    Net unrealized loss on investments, net of tax(86)— (86)   Foreign currency translation adjustments— 1,094 1,094 Balance at March 31, 2025$104 $1,247 $1,351 Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2023$124 $123 $247    Net unrealized loss on investments, net of tax (1)(108)— (108)   Foreign currency translation adjustments— 13 13 Balance at March 31, 2024$16 $136 $152 (1) Net of a nominal tax benefit for both the three months ended March 31, 2025 and 2024. Share Repurchase ProgramsOn May 7, 2024, the Company announced that its Board of Directors approved a share repurchase program which authorized